Literature DB >> 27664245

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Novello1, F Barlesi2, R Califano3, T Cufer4, S Ekman5, M Giaj Levra6, K Kerr7, S Popat8, M Reck9, S Senan10, G V Simo11, J Vansteenkiste12, S Peters13.   

Abstract

Entities:  

Year:  2016        PMID： 27664245     DOI： 10.1093/annonc/mdw326

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  294 in total

Review 1.  Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.

Authors:  Alex Friedlaender; Giuseppe Luigi Banna; Lucio Buffoni; Alfredo Addeo
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

2.  Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Authors:  Barbara Melosky; Rosalyn Juergens; Vera Hirsh; Deanna McLeod; Natasha Leighl; Ming-Sound Tsao; Paul B Card; Quincy Chu
Journal:  Oncologist       Date:  2019-05-28

Review 3.  Alectinib: A Review in Advanced, ALK-Positive NSCLC.

Authors:  Julia Paik; Sohita Dhillon
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

4.  Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?

Authors:  G Kasymjanova; R T Jagoe; C Pepe; L Sakr; V Cohen; D Small; T M Muanza; J S Agulnik
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

5.  Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.

Authors:  Ales Ryska; Rares Buiga; Albena Fakirova; Izidor Kern; Włodzimierz Olszewski; Lukas Plank; Sven Seiwerth; Erika Toth; Eri Zivka; Christiane Thallinger; Christoph Zielinski; Luka Brcic
Journal:  Oncologist       Date:  2018-08-03

6.  Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Authors:  Daniele Magnini; Leonello Fuso; Francesco Varone; Ettore D'Argento; Maurizio Martini; Antonietta Pecoriello; Vincenzo Di Noia; Damiano Arciuolo; Guido Fadda; Guido Rindi; Luca Richeldi
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

7.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Authors:  Marina Chiara Garassino; Byoung-Chul Cho; Joo-Hang Kim; Julien Mazières; Johan Vansteenkiste; Hervé Lena; Jesus Corral Jaime; Jhanelle E Gray; John Powderly; Christos Chouaid; Paolo Bidoli; Paul Wheatley-Price; Keunchil Park; Ross A Soo; Yifan Huang; Catherine Wadsworth; Phillip A Dennis; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2018-03-12       Impact factor: 41.316

8.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

9.  Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.

Authors:  Koji Nishimoto; Masato Karayama; Naoki Inui; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Nao Inami; Shun Matsuura; Yusuke Kaida; Takashi Matsui; Kazuhiro Asada; Hiroyuki Matsuda; Masato Fujii; Mikio Toyoshima; Shiro Imokawa; Takafumi Suda
Journal:  Med Oncol       Date:  2018-06-16       Impact factor: 3.064

10.  Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Authors:  Glenwood D Goss; Enriqueta Felip; Manuel Cobo; Shun Lu; Konstantinos Syrigos; Ki Hyeong Lee; Erdem Göker; Vassilis Georgoulias; Wei Li; Salih Guclu; Dolores Isla; Young Joo Min; Alessandro Morabito; Andrea Ardizzoni; Shirish M Gadgeel; Andrea Fülöp; Claudia Bühnemann; Neil Gibson; Nicole Krämer; Flavio Solca; Agnieszka Cseh; Eva Ehrnrooth; Jean-Charles Soria
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.